Investigator/CRO Financial Disclosure Required By FDA; Feb. Rule Expanded
Executive Summary
Investigators must report all financial arrangements with contract research organizations that are acting as primary or joint sponsors of studies, according to an Oct. 26 FDA draft guidance on "Financial Disclosure By Clinical Investigators."
You may also be interested in...
Advisory Cmte. Conflict-Of-Interest Waiver Details Should Be Public – Bristol
FDA advisory committee members granted conflict-of-interest waivers should be required to disclose the companies to which they have financial ties, Bristol-Myers Squibb said in comments to FDA
Advisory Cmte. Conflict-Of-Interest Waiver Details Should Be Public – Bristol
FDA advisory committee members granted conflict-of-interest waivers should be required to disclose the companies to which they have financial ties, Bristol-Myers Squibb said in comments to FDA
Investigator/Firm Financial Ties May Trigger Heavier Scrutiny Of Data By FDA
Disclosure of financial arrangements between a clinical investigator and study sponsor will lead to a more stringent product review at FDA, Office of Drug Evaluation I Associate Director-Regulatory Affairs Linda Carter told the Food & Drug Law Institute.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: